Skip to main
OMER
OMER logo

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corp has demonstrated a significant clinical advancement with its drug candidate narsoplimab, showing statistically significant survival advantages in patients with transplant-associated thrombotic microangiopathy, which enhances the company's credibility and competitive positioning in the therapeutic market. The encouraging Phase 2 results of Zaltenibart also highlight the safety and potential superiority of emerging treatments, with the possibility of reaching billions in market opportunities if efficacy and safety are proven. Overall, Omeros’s strategic focus on complement-mediated diseases and advancements in clinical evidence strongly supports a positive outlook on the company’s future financial performance.

Bears say

Omeros Corp has experienced considerable operating losses and is not expected to achieve profitability for several more years, indicating a challenging financial outlook. The company's drug candidate, narsoplimab, faces skepticism regarding its potential FDA approval due to an unconventional development trajectory and insufficient clinical data, particularly after more than four years since the Complete Response Letter (CRL). Additionally, Omeros is likely to require substantial further capital for research and development and commercialization efforts, raising concerns about potential ownership dilution for existing shareholders.

Omeros (OMER) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Nov 9, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.